Verdad Advisers’s Structure Therapeutics GPCR Stock Holding History

Verdad Advisers’s Portfolio GPCR Stock Details GPCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$608K	Hold	11,335	–	–	0.58%	59
2026 Q1	$546K	Buy	+11,335	New	+$776K	0.62%	58

Other funds holding GPCR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Jupiter Topco New York $245B AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Verdad Advisers's GPCR Position: Q2 2026 in Review

Verdad Advisers held its Structure Therapeutics (GPCR) position steady in Q2 2026 at 11,335 shares worth $608K. The position accounts for 0.58% of the portfolio, ranked #59.

Verdad Advisers first reported a position in GPCR in Q1 2026 and has held it in 2 quarters since. 192 funds tracked by Wall St. Rank hold GPCR as of Q2 2026.

Verdad Advisers held 11,335 shares of Structure Therapeutics worth $608K as of Q2 2026.
Verdad Advisers left its Structure Therapeutics share count unchanged in Q2 2026.
Structure Therapeutics made up 0.58% of Verdad Advisers's portfolio in Q2 2026, its #59 holding.
Verdad Advisers first reported a position in Structure Therapeutics in Q1 2026 and has held it in 2 quarters since.
192 funds tracked by Wall St. Rank held Structure Therapeutics as of Q2 2026.

Based on Verdad Advisers's 13F filing for Q2 2026, filed 14 Aug 2026.